Multidimensional AMS Evaluation Framework Under China's Evolving Policy Landscape supports hospital teams in China to improve antimicrobial stewardship through quality improvement projects for better inpatient care.
Funder: Pfizer Inc.
Due Dates: January 8, 2027 (Submission, 23:59 EST) | March 12, 2027 (Anticipated notification) | June 12, 2027 (Anticipated start) | June 12, 2029 (Anticipated end)
Funding Amounts: Up to $59,000 per project for Streams 1–2 or $30,000 for Stream 3; maximum two years; estimated total budget $295,000
Summary: Supports implementation science-informed quality improvement projects that translate antimicrobial stewardship evidence into routine hospital care in mainland China.
Key Information: Applicant organizations must be legally able to receive funding directly from Pfizer Investment Co., Ltd.; individuals and independent medical practice groups are ineligible.
Pfizer’s competitive quality improvement program supports hospital-based antimicrobial stewardship (AMS) projects in mainland China. It aims to close the gap between established evidence and routine inpatient care by incorporating elements of implementation science. Projects should improve evidence-based clinical practice, hospital-level management, or healthcare professionals’ awareness and readiness, with the goal of creating sustained, scalable improvements.
Each proposal must address one of three streams: bedside implementation of the WHO → START → ADJUST → STOP pathway, hospital-level AMS management, or professional awareness and implementation readiness. The primary audiences include physicians, clinical pharmacists, microbiology and laboratory professionals, infection prevention and control professionals, and multidisciplinary AMS teams. The ultimate beneficiaries are hospitalized adults receiving antimicrobial therapy. Clinical research and projects evaluating therapeutic or diagnostic agent efficacy are not supported.